3 completed. 3 Phase 3.
By phase and status
Follow Trastuzumab IV: new trials by email Literature Review of Trastuzumab IV trials Research Report on Trastuzumab IV
Trials (filtered) newest first · largest first
All 3 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV - Early Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Completed | 346 | 2022-07-05 | 2026-02-10 |
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Pertuzumab IV, Trastuzumab IV, Pertuzumab and Trastuzumab FDC SC - HER2-positive Early Breast Cancer | Phase 3 | Completed | 200 | 2020-02-05 | 2026-02-20 |
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
Cyclophosphamide, Doxorubicin, Docetaxel - Early Breast Cancer | Phase 3 | Completed | 500 | 2018-06-14 | 2024-06-26 |
Conditions studied
Breast Neoplasms (2) · Inflammatory Breast Neoplasms (1) · Patient Preference (1)
Sponsors
Hoffmann-La Roche (3)
Countries
Argentina (2) · Brazil (2) · Canada (2) · Mexico (2) · South Korea (2) · Spain (2) · Belgium (1) · Bosnia and Herzegovina (1) · Bulgaria (1) · Chile (1) · China (1) · Costa Rica (1) · Croatia (1) · Czechia (1) · France (1)
Results publications
PMID 33357420
NIH funding
2017 (1), 2023 (1)